Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – ...

Shares of Arvinas Inc. (ARVN) fell 4% on Thursday as Wall Street sounded contradicting opinions on the future of its ...

Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – ...

Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

Arvinas believes the differentiated pharmacology of ARV-471, including its iterative degradation activity, has the potential to translate into meaningful clinical benefit for patients.

--Arvinas, Inc. and Pfizer Inc. today announced clinical data for vepdegestrant, a novel oral PROteolysis TArgeting Chimera estrogen receptor degrader, in combination with palbociclib. "We are ...

--Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced updated safety and initial efficacy data contained in ...

Arvinas' PROTAC approach has several advantages over conventional drugs, including the potential to target "undruggable" proteins, achieve tissue-specific targeting, and cross the blood-brain barrier.

Arvinas Gathers $55 Million for Prostate, Breast Cancer Trials Investors placing another bet on the emerging protein-degradation market By Brian Gormley April 4, 2018 7:30 am ET | WSJ Pro ...

NEW HAVEN, Conn. and NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced clinical data for vepdegestrant (ARV-471), a novel oral ...